Aummune is a clinical stage company developing a first-of-its-kind approach for individualized treatment of solid tumors.

Its proprietary platform utilizes a unique efficacy-driven selection process to match and produce a patient-specific tri-functional oligonucleotide drug that safely and synergistically induces cancer cell death and activates both innate and adaptive immune responses.Aummune’s lead program, AM003, has already initiated its Phase 1 clinical trial following successful demonstrations of efficacy and safety in multiple animal models.

The company is now actively recruiting patients for this First-in-Human study, which targets those with locally advanced and metastatic solid tumors.